Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Summary

The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it aims to answer are: * Does this therapy have a promising efficacy? * Does this therapy have a manageable toxicity? Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer.

Timeline

Start

2022-12-01

Primary completion

2024-08-31

Completion

2025-08-31

Drugs

Indications